A federal appeals court heard oral arguments last week in a case that could carve out more guidance on whether state law claims involving labels on pharmaceuticals are pre-empted.
To argue the case on Oct. 3 before the U.S. Court of Appeals for the Ninth Circuit, both sides brought in appellate heavyweights from Washington D.C.: David Frederick of Kellogg Hansen Todd Figel & Frederick for the plaintiffs and Kannon Shanmugam of Williams & Connolly for the defendants, which include Merck Sharp & Dohme Corp. and Eli Lilly and Co.
